Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Acrocephalosyndactylia 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × infigratinib × Clear all
NCT02312804 2015-02-16

Ph Ib/BGJ398/Cervix and Other Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡